TheTechno Optimist.

BarostimCVRx—CVRx Q2 2026 revenue rises 16% to $15.7M but full-year guidance is cut to $58-60MBarostimCVRx—CVRx enrols first patient in BENEFIT-HF, a 2,500-patient trial of Barostim in a wider heart failure population

Barostim

by CVRxUS

Treat heart failure through the nervous system: trigger the body's own blood-pressure reflex to cut the nerve drive that wears out a weak heart, improving how patients feel and, if BENEFIT-HF succeeds, survival.

ScalingStage 5 of 5

Sold at 258 US centres; 2,500-patient BENEFIT-HF outcomes trial enrolling since May 2026

Updated 6 Aug 2026Checked 11 Oct0 updates this week

Milestones

Next · Enrol 2,500 patients at ~150 US and German centres
  1. FDA approval for heart failure (BeAT-HF data)16 Aug 2019Complete.
  2. Category I CPT codes replace Category III1 Jan 2026Complete.
  3. First BENEFIT-HF patient enrolled4 May 2026Complete.
  4. Humana and Devoted Medicare Advantage coverageJul 2026Complete.
  5. Enrol 2,500 patients at ~150 US and German centresNowCurrent milestone.
  6. BENEFIT-HF completesTarget 2032Not yet reached.

Most important updates

Upcoming

  1. 2032BENEFIT-HF completes (next)
  2. 2032BENEFIT-HF trial completion
Primer